BiomX Inc. (NYSE AMERICAN: PHGE)
$0.5700
+0.0006 ( +0.60% ) 43.9K
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Market Data
Open
$0.5700
Previous close
$0.5694
Volume
43.9K
Market cap
$10.91M
Day range
$0.5680 - $0.6160
52 week range
$0.4800 - $8.5500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
pre | Proxies and info statements | 23 | May 28, 2024 |
4 | Insider transactions | 1 | May 20, 2024 |
10-q | Quarterly Reports | 70 | May 20, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
nt | Quarterly Reports | 1 | May 15, 2024 |
8-k | 8K-related | 16 | Apr 15, 2024 |
3 | Insider transactions | 1 | Apr 15, 2024 |
10-k | Annual reports | 123 | Apr 04, 2024 |
8-k | 8K-related | 15 | Apr 03, 2024 |
nt | Quarterly Reports | 1 | Apr 01, 2024 |